In RCTs of statin therapy for mild to moderate AS, although aortic valve event rates were not reduced, the rate of ischemic events was reduced by about 20% in the statin therapy group even though these patients did not meet standard cri- teria for statin therapy.4 6,14,15 3. In patients undergoing TAVI, observational and registry data show that those who were treated with renin angiotensin system blocker therapy after the procedure had a lower 1-year mortality rate than those not treated with renin angio- tensin system blocker therapy, with a rela- tive risk reduction of about 20% to 50% and an absolute risk reduction between 2.4% and 5.0%. When stratified by LVEF, having a pre- scription for a renin angiotensin system inhibi- tor, versus no prescription, was associated with a lower 1-year mortality rate among patients with preserved LVEF but not among those with 4. Despite experimental models and retrospective clinical studies suggesting that lipid-lowering therapy with a statin might prevent disease pro- gression of calcific AS, 3 large well-designed RCTs failed to show a benefit, either in terms of changes in hemodynamic severity or in clinical outcomes, in patients with mild to moderate valve obstruc- tion. Thus, at the time of publication, there are no data to support the use of statins for prevention of progression of AS.7,8,16,17 3.2.3. Timing of Intervention Recommendations for Timing of Intervention of AS Referenced studies that support the recommendations are summarized in Online Data Supplements 4 and 6 to 10. 